https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/news

The Latest

patient with COVID-19

HIV Status Does Not Affect COVID-19 Hospitalization, Short-Term Outcomes in Connecticut Hospital

The findings add to a growing body of research showing that it’s other co-morbidities, not HIV, that lead to worse health outcomes from COVID-19—at least among individuals who are on stable antiretroviral therapy.

By Larry Buhl
COVID-19 mask profile

This Week in HIV Research: The Real-World Effects of COVID-19

Oct. 22, 2020: Impact of COVID-19 shutdowns on HIV viral suppression; unsuppressed HIV viral load despite no treatment failure; point-of-care rapid testing vs. lab testing; it's not about "what," it's about "when."

By Barbara Jungwirth and Myles Helfand
reflect rethink revise

This Week in HIV Research: Revisiting Our Needs

Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.

By Barbara Jungwirth and Myles Helfand
smoking

Smoking Rates Are Higher in the LGBTQ Community; Can More Inclusive Data Help?

Scout, Ph.D., the head of the National LGBT Cancer Network, lays out the current state of the interplay between nicotine, cancer, HIV, and people who are LGBTQ.

By Terri Wilder, M.S.W.
prison

Hepatitis C Treatment Barriers Persist Through the Cure Era, Especially in U.S.

For the most vulnerable populations disproportionately impacted by HCV in the U.S.—i.e., incarcerated people and people who inject drugs—treatment remains dangerously elusive, experts say.

By Ginger Skinner
Robert Redfield

Robert Redfield’s Epic COVID Failure Is Not a Surprise to Many HIV and Public Health Experts

They say that the longtime HIV researcher already had a sketchy record that made him the perfect Trump flunky.

By Tim Murphy
monoclonal antibodies

Are Monoclonal Antibodies the Future of COVID-19 Treatment?

Infectious-diseases researcher David Wohl, M.D., talks about a major COVID-19 treatment trial in the works—and how it relates to our efforts against HIV.

By Terri Wilder, M.S.W.
BLM health care

This Week in HIV Research: The Long Road to Racial Health Justice

Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.

By Barbara Jungwirth and Myles Helfand
Hep C virus

This Week in HIV Research: Hep C, That Other Epidemic Within an Epidemic

Sept. 3, 2020: A hepatitis C microelimination program for people living with HIV; PrEP concentrations and gender-affirming hormones; a collaborative intervention to improve opioid prescribing practices; TDF and fracture risk.

By Barbara Jungwirth and Myles Helfand
doctor with trans patient

This Week in HIV Research: When Treating Trans Patients, Check Your Priors

Aug. 27, 2020: Traditional CVD risk calculation tools falter for transgender women; switching to B/F/TAF despite NRTI resistance; how tenofovir has altered the HBV landscape; syndemic effects on viral load and blood pressure.

By Barbara Jungwirth and Myles Helfand